Form 4: Acadia Pharmaceuticals Director Daniel Soland Reports Equity Transactions, Including RSU Vesting and New Grants

Acadia Pharmaceuticals Inc. Director Daniel B. Soland reported the vesting of restricted stock units and the grant of new stock options and restricted stock units, increasing his beneficial ownership of common stock.

Summary

• Daniel B. Soland, a Director of ACADIA PHARMACEUTICALS INC. (ACAD), reported transactions on May 29, 2025.
• He acquired 9,387 shares of common stock through the vesting of previously granted restricted stock units (RSUs).
• Following this transaction, Mr. Soland beneficially owns 44,041 shares of common stock directly.
• Concurrently, 9,387 restricted stock units were disposed of as they vested in full on May 29, 2025, the date of the annual meeting of stockholders.
• Mr. Soland was granted 13,793 Director Stock Options with an exercise price of $22.29 per share, which will vest quarterly over one year following the grant date or the next annual meeting.
• He also received a new grant of 8,107 restricted stock units, which will vest in full on the earlier of one year following the grant date or the next annual meeting of stockholders.

Sentiment

Score: 6

Explanation: The document reports routine insider equity transactions, including the vesting of existing awards and the grant of new compensation. This is generally a neutral to slightly positive event as it aligns director interests with shareholders, but it does not indicate significant operational or financial news.

Positives

• The grant of new stock options (13,793 units) and restricted stock units (8,107 units) to a director aligns management's interests with shareholders, as their compensation is tied to the company's future performance.
• The vesting of 9,387 restricted stock units indicates a successful completion of prior performance or service conditions.

Future Outlook

The newly granted stock options will vest quarterly over one year following the grant date, with the final tranche vesting on the earlier of one year following the grant date or the next annual meeting of stockholders. The new restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders.

Industry Context

This Form 4 filing represents a routine insider compensation event for a director at a publicly traded pharmaceutical company. Such equity grants are common practice across industries to incentivize and retain key personnel by aligning their financial interests with long-term shareholder value.

Comparison to Industry Standards

• The structure of equity compensation, including restricted stock units and stock options with vesting schedules, is a standard practice for director compensation in the biotechnology and pharmaceutical sectors, similar to companies like Biogen Inc. or Gilead Sciences, Inc. This approach aims to align director incentives with long-term company performance and shareholder returns.
• The vesting schedule for the new stock options (quarterly over one year) and RSUs (full vesting on earlier of one year or next annual meeting) is typical for annual director grants, reflecting a common approach to retain and incentivize board members over a defined period.

Stakeholder Impact

• Shareholders: The equity grants to the director align his interests with those of the shareholders, potentially encouraging decisions that enhance long-term shareholder value.

Next Steps

• The newly granted Director Stock Options will begin vesting quarterly over the next year.
• The newly granted Restricted Stock Units will vest in full on the earlier of one year from the grant date or the next annual meeting of stockholders.

Key Dates

Keywords

Acadia Pharmaceuticals, ACAD, Form 4, SEC filing, insider transaction, restricted stock units, RSU, stock options, equity compensation, director, beneficial ownership